These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 37205910)

  • 1. Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma.
    Murdaugh RL; Anastas JN
    Front Pharmacol; 2023; 14():1002296. PubMed ID: 37205910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developmental origins and oncogenic pathways in malignant brain tumors.
    Lu QR; Qian L; Zhou X
    Wiley Interdiscip Rev Dev Biol; 2019 Jul; 8(4):e342. PubMed ID: 30945456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
    Wood MD; Beadling C; Neff T; Moore S; Harrington CA; Baird L; Corless C
    Acta Neuropathol Commun; 2023 Sep; 11(1):143. PubMed ID: 37670377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
    Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
    Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development.
    Binder H; Willscher E; Loeffler-Wirth H; Hopp L; Jones DTW; Pfister SM; Kreuz M; Gramatzki D; Fortenbacher E; Hentschel B; Tatagiba M; Herrlinger U; Vatter H; Matschke J; Westphal M; Krex D; Schackert G; Tonn JC; Schlegel U; Steiger HJ; Wick W; Weber RG; Weller M; Loeffler M
    Acta Neuropathol Commun; 2019 Apr; 7(1):59. PubMed ID: 31023364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumor micro-environment in pediatric glioma: friend or foe?
    Messiaen J; Jacobs SA; De Smet F
    Front Immunol; 2023; 14():1227126. PubMed ID: 37901250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response.
    Johnson KC; Anderson KJ; Courtois ET; Gujar AD; Barthel FP; Varn FS; Luo D; Seignon M; Yi E; Kim H; Estecio MRH; Zhao D; Tang M; Navin NE; Maurya R; Ngan CY; Verburg N; de Witt Hamer PC; Bulsara K; Samuels ML; Das S; Robson P; Verhaak RGW
    Nat Genet; 2021 Oct; 53(10):1456-1468. PubMed ID: 34594038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies.
    Persson ML; Douglas AM; Alvaro F; Faridi P; Larsen MR; Alonso MM; Vitanza NA; Dun MD
    Neuro Oncol; 2022 Sep; 24(9):1408-1422. PubMed ID: 35481923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells.
    Petővári G; Dankó T; Krencz I; Hujber Z; Rajnai H; Vetlényi E; Raffay R; Pápay J; Jeney A; Sebestyén A
    Pathol Oncol Res; 2020 Jan; 26(1):23-33. PubMed ID: 31187466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit.
    Groves A; Cooney TM
    Front Cell Dev Biol; 2022; 10():1089898. PubMed ID: 36589742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma.
    Pachocki CJ; Hol EM
    J Neuroinflammation; 2022 Nov; 19(1):276. PubMed ID: 36403059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive profiling of stem-like features in pediatric glioma cell cultures and their relation to the subventricular zone.
    Da-Veiga MA; Coppieters N; Lombard A; Rogister B; Neirinckx V; Piette C
    Acta Neuropathol Commun; 2023 Jun; 11(1):96. PubMed ID: 37328883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
    Plant-Fox AS; O'Halloran K; Goldman S
    Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioma epigenetics: From subclassification to novel treatment options.
    Gusyatiner O; Hegi ME
    Semin Cancer Biol; 2018 Aug; 51():50-58. PubMed ID: 29170066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Growing Relevance of Immunoregulation in Pediatric Brain Tumors.
    Melcher V; Kerl K
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.
    Rechberger JS; Bouchal SM; Power EA; Nonnenbroich LF; Nesvick CL; Daniels DJ
    Expert Opin Ther Targets; 2023; 27(11):1071-1086. PubMed ID: 37897190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse Glioma Heterogeneity and Its Therapeutic Implications.
    Nicholson JG; Fine HA
    Cancer Discov; 2021 Mar; 11(3):575-590. PubMed ID: 33558264
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.